Successful Use of Gonadotropin-Releasing Hormone Agonist in a Patient with Pulmonary Endometriosis

T Koizumi, Tomonobu Koizumi, Koizumi T, Hiroshi Inagaki, Inagaki H, H Inagaki, Y Takabayashi, Takabayashi Y, Yasuki Takabayashi, K Kubo, Keishi Kubo, Kubo K
Respiration; international review of thoracic diseases · 1999 · vol. 66(6) , pp. 544–546 · doi:10.1159/000029433 · PMID:10575342 · W2082323105
article OA: closed CC0 ⤵ 21 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-18 ⓘ

A 26-year-old female with recurrent chest symptoms coinciding with menstruation, diagnosed as pulmonary endometriosis, was successfully treated with a GnRH agonist for six months and remained asymptomatic for 16 months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A 26-year-old single female was admitted to hospital with recurrent chest pain, cough and hemoptysis. The symptoms developed 5 months before admission coinciding with menstruation. The disease was diagnosed as pulmonary endometriosis. She was treated with a long-acting gonadotropin-releasing hormone analogue (GnRH agonist; sustained-release leuprolide acetate, 3.75 mg/month, i.m.) for 6 months. She remained asymptomatic for 16 months with regular menstruation even after discontinuing the treatment. This indicates that the initial treatment of pulmonary endometriosis with a GnRH agonist is an acceptable medical alternative, especially in patients with a short duration of the disease from the onset of the chest symptoms.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Leuprolide Lung Diseases Adult Delayed-Action Preparations Drug Administration Schedule Endometriosis Female Follow-Up Studies Humans Leuprolide Lung Diseases Lung Diseases Tomography, X-Ray Computed

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (10)

Cited by (21)

Source provenance

europepmc
last seen: 2026-07-29T06:27:48.050232+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:24.024533+00:00
License: CC0 · commercial use OK